Contraceptive Technology Update 2015-02 - Contraceptive Technology Update - Feb 01, 2015

Target Audience:

This activity is intended for OB/GYNs, nurses, nurse practitioners, and other family planners.


AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Listing:

Consulting Editor
Andrew M. Kaunitz, MD
Professor and Associate Chairman
Department of OB/GYN
University of Florida College of Medicine

Rebecca Bowers

Executive Editor
Joy Dickinson
AHC Media

Nurse Reviewer
Melanie Deal, MS, WHNP-BC, FNP
Nurse Practitioner
San Francisco State University Student Health Services
San Francisco


  • For methods that are reversible and long-acting, upswing continues
  • CTU remembers Michael Rosenberg, MD, MPH
  • Contraceptive Survey Profile
  • Ortho Evra patch discontinued — What next?
  • With unsurpassed efficacy and rapid reversibility, contraceptive implant can be put into practice
  • Oral contraceptives — Should they be OTC?
  • Despite new options, oral contraceptive pills are still in birth control mix, survey respondents say


  • Identify clinical, legal, or scientific issues related to development and provisions of contraceptive technology or other reproductive services
  • Describe how those issues affect services and patient care
  • Integrate practical solutions to problems and information into daily practices, according to advice from nationally recognized family planning experts
  • Provide practical information that is evidence-based to help clinicians deliver contraceptives sensitively and effectively

Financial Disclosure:

Consulting Editor Andrew M. Kaunitz, MD, discloses that he is a retained consultant for Actavis, Teva Pharmaceutical Industries Ltd., Merck, and Bayer; he receives grant/research support from Bayer, Trimel, and TherapeuticsMD; and he receives royalties from UpToDate. Author Rebecca Bowers, and Executive Editor Joy Dickinson report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study. Melanie Deal, nurse reviewer, discloses that she is on the speakers bureau for Actavis and Merck & Co. and the advisory board for Actavis, Teva, and Hologic. Melanie Gold, guest columnist, reports that she is on the speaker’s bureau for Novartis. Anita Brakman, guest columnist, has no relevant relationships to disclose.

Copyright 2014, AHC Media. All rights reserved.